Zauner 2002.

Methods	Study design: parallel RCT Duration of study: commenced 1986 Duration of follow‐up: 10 years
Participants	Country: Germany Setting: multicentre Inclusion criteria: clinical picture of biopsy‐proven RPGN and Couser Type II or III (immune deposits or pauci‐immune respectively) Number: treatment group (21); control group (18) Mean age: 52.3 years Sex (M/F): 25/14 Exclusion criteria: Couser Type I GN (linear GBM Ab staining on biopsy); previous immunosuppression or PE
Interventions	Treatment group Immunosuppression as for control group PE: 40 mL/kg with FFP replacement daily for 3 exchanges, continued if no response to a maximum of 12 exchanges; mean number of PE = 6 Control group IV MP: 500 mg/day for 3 days. Prednisolone 80, 60 then 40 mg/day for a week each. Dose tapered by 5 mg/day each week to maintenance dose of 10 mg/day CPA: 2 mg/kg/day oral from day 1; dose reduced for side effects. Continued for 6 months after remission Subsequent maintenance therapy is not mentioned
Outcomes	Death ESKD SCr Adverse events
Notes	No results were extractable from the published paper Funding source: not reported
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Insufficient information to permit judgement
Allocation concealment (selection bias)	Unclear risk	Insufficient information to permit judgement
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Open‐label study, unable to blind interventions; unlikely to affect outcomes
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Insufficient information to permit judgement
Incomplete outcome data (attrition bias) All outcomes	Low risk	All patients accounted for
Selective reporting (reporting bias)	High risk	Data could not be extracted for analysis
Other bias	Unclear risk	Funding source not reported